Capmatinib for non-small cell lung cancer
-
N. Alzofon [1] ; A. Jimeno [1] [2]
-
[1] Division of Medical Oncology, Department of Medicine, Charles C. Gates Center for Regenerative Medicine
-
[2] Stem Cell Biology, University of Colorado School of Medicine, Aurora, Colorado, USA
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 1, 2021, págs. 17-25
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Molecular profiling of non-small cell lung cancer (NSCLC) in the past decade has revealed numerous oncogenic driver events in NSCLC leading to several highly effective therapies. While a promising target, small-molecule inhibition of MET signaling has proven difficult. Capmatinib is a specific inhibitor of MET with Food and Drug Administration (FDA) accelerated approval in 2020 for the treatment of NSCLC harboring MET exon 14 skipping mutations. As a first-line therapy, 68% of patients in phase II clinical trials responded to capmatinib with a median duration of 12.6 months and a manageable safety profile. Although FDA approval is currently limited to MET exon 14 skipping mutations, capmatinib has shown potential in other subsets of MET- dysregulated NSCLC for which ongoing studies are underway. This review covers the preclinical and early clinical data leading to capmatinib’s approval, discusses the management of treatment-related toxicities, and offers potential avenues of further research.
